PATENT CLAIM ANALYSIS

Application Number: 16164451
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-06
Patent Classification: ["600", "001000"]

Abstract:
Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

Claim (Index 32):
The method of  claim 29 , wherein the cancer is selected from breast cancer, colon cancer, colorectal carcinomas, non-small cell lung cancer, small-cell lung cancer, kidney cancer, bladder and urethra cancer, liver cancer, ovarian cancer, prostate cancer, uterine cervix cancer, urinary bladder cancer, gall bladder carcinoma, gastric carcinoma, esophageal cancer, gastrointestinal stromal tumor, pancreatic cancer, germ cell tumors, mast cell tumors, neuroblastoma, retinoblastoma, mesothelioma, mastocytosis, testicular cancers, glioblastomas, astrocytomas, sarcoma, osteosarcoma, B cell lymphoma, T cell lymphoma, NK cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, melanoma, basal cell carcinoma, skin cancer, myeloma, leukemia, acute myelocytic leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome, chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML).

Metadata:
- Claim Count in Document: 62.0
- Percentile: 97.0
- Lexical Diversity: 1.15385
- Patent Class: 600.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15386834', '12761588', '14069233', '14344314', '11853700']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.523966485760111
- 35 USC 102 Novelty (BERT): 0.5412994161014716
- Combined Prediction Score: 0.525699778794247
- Mean Citation Score: 353.43056799999994
- Max Citation Score: 412.8129
- Similarity Product: 328.54444561765195

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test